Skip to main content

Table 1 Demographics, breast cancer, tamoxifen use and co-medications use characteristics in the overall population in the study

From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

Characteristics (N= 245) N/mean Percent/SD
Mean age (years) a 47.46 ± 9.7
Self-report ethnicity   
   Caucasian 166 67.76
   Asian/East Asian 56 22.86
   African American/Black 2 0.82
   Latina/Hispanic 14 5.71
   Pacific Islander 1 0.41
   Other/mixed 3 1.22
   Declined/refused/do not know 3 1.22
Number married (yes) 176 72
Number full-time working 98 40
Education levels   
   High school graduated or less 6 2.45
   Some college 36 14.69
   College graduated 90 36.73
   Completed post-graduate degree 105 42.86
   Declined/refused 8 3.27
Socio-economic status   
   Income < $50, 000 29 11.84
   Income ≥$50, 000 to < $100, 000 56 22.86
   Income ≥$100, 000 108 44.07
   Declined/refused 52 21.23
Reported other health problems 91 38
Breast cancer characteristics   
   Breast cancer (yes) 237 97
   Had invasive breast cancer 165 70
   Surgery (yes) 231 98
   Had lumpectomy 119 52
Menopausal status at diagnosis   
   Pre-menopausal 184 78
   Post-menopausal 51 22
Mean age at menopause (years) a 45.61 ± 6.79
Had natural menopause 35 22.73
Menopause due to chemotherapy treatment 74 48.05
Previous used of hormone therapy 37 15
Tamoxifen use   
   Ever prescribed 191 78
   Ever taken 171 70
   Currently taking 166 68
Common side effects attributed to tamoxifen   
   Hot flashes 154 63
   Sleep problems 113 46
   Vaginal dryness 90 37
Co-medications/ CYP2D6 inhibitors   
   Strong inhibitors   
Paroxetine 1 0.41
Bupropion 8 3.26
   Moderate inhibitors   
Sertraline 8 3.26
Duloxetine 3 1.22
   All other inhibitors   
Amitriptyline 2 0.82
Amlodipine 2 0.82
Celecoxib 2 0.82
Ceterizine 2 0.82
Citalopram 6 2.45
Diphenhydramine 3 1.22
Escitalopram 6 2.45
Imipramine 1 0.41
Loratadine 3 1.22
Nortriptyline 1 0.41
Ranitidine 1 0.41
   Other co-medications   
Gabapentin 10 4.00
Trazodone 2 0.82
Venlafaxine 15 6.12
Referral method   
   Physician/nurse referral 196 80
   Self-referred or breast cancer support group referral 11 4
   Study contact letter 38 16
Previous knowledge of CYP2D6 testing (yes) 122 50
Source of CYP2D6 testing knowledge   
   Physician or nurse 46 38
   Newspaper 5 4
   Television 1 1
   Internet 17 14
   Medical literature 24 20
   Other 27 22
   Unknown/missed 2 1
  1. aData presented as mean ± SD. N, number of participants in the study; SD, standard deviation.